African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre l'onchocercose JOINT ACTION FORUM JAF-FAC FORUM D'ACTION COMMUNE Office of the Chairman Bureau du Président JOINT ACTION FORUM JAF12.10 Twelfth session ORIGINAL: ENGLISH Dar-es-Salaam (Tanzania), 5-8 December 2006 October 2006 Item 10 of the Provisional Agenda PARTNERS’ MEETING REPORT
i JOINT ACTION FORUM Office of the Chairman JAF-FAC: TWELFTH SESSION Dar-es-Salaam, 5-8 December, 2006 FORUM D’ACTION COMMUNE Bureau du Président PARTNERS’ MEETING REPORT 26-27 SEPTEMBER, 2006 African Programme for Onchocerciasis Control Programme africain de lutte contre l’onchocercose JAF12.10 ORIGINAL: ENGLISH October 2006
JAF12.10 Page i INTRODUCTION ................................................................................................................................................1 SUMMARY OF SESSIONS ................................................................................................................................2 OPENING SESSION: APOC AT A CROSSROADS ...................................................................................................2 SESSION 1: THE POTENTIAL EXPANSION OF APOC ACTIVITIES BEYOND THE YEAR 2010 AND THE STRENGTHENING OF ITS MANDATE AND CAPACITY .............................................................................................5 SESSION 2: THE POTENTIAL ROLE FOR APOC IN PROMOTING INTEGRATION OF CDTI WITH PRIMARY HEALTH INFRASTRUCTURE AND THE CO-IMPLEMENTATION OF ONCHOCERCIASIS AND OTHER HEALTH INTERVENTIONS..7 SESSION 3: THE POTENTIAL EXPANSION OF THE GEOGRAPHIC MANDATE OF APOC TO FORMER ONCHOCERCIASIS CONTROL PROGRAM (OCP) COUNTRIES ................................................................................9 SESSION 4: A PROPOSED STRATEGIC PLAN FOR APOC FOR 2007-2015 AND THE FUTURE FINANCING NEEDS OF APOC...............................................................................................................................................................12 CLOSING CEREMONY: GENERATING CONSENSUS STATEMENTS ON THE FUTURE OF ONCHOCERCIASIS CONTROL .........................................................................................................................................................................14 SUMMARY OF DECLARATIONS .................................................................................................................15 APPENDIX .........................................................................................................................................................18
JAF12.10 Page 1 INTRODUCTION The following document is a Report of the Special Meeting of the Partners (hereafter the Meeting) of the African Programme for Onchocerciasis Control (APOC), held in Yaoundé, Cameroon, 26-27 September 2006. The Meeting brought together various Partners of APOC, including Ministers of Health from across Africa, as well as their representatives, and representatives from Donor Agencies, Non-Governmental Development Organizations (NGDOs), APOC management, national onchocerciasis coordinators, Merck & Co., the international Neglected Tropical Disease (NTD) community, and the private sector (see Appendix for a List of Participants). The goal of the Meeting was to share with the Partners the findings and recommendations of a report produced by the Working Group entitled “A Strategic Overview of the Future of Onchocerciasis Control in Africa” (hereafter the Strategy Paper) to be presented to the Joint Action Forum (JAF), APOC’s governing body, later this year. At the request of the JAF and the Committee of Sponsoring Agencies (CSA), the Working Group had been appointed to reflect upon a number of challenges and critical issues identified in the external evaluation of APOC and the Mid-term evaluation of the Special Intervention Zones (SIZ) of the former OCP countries (see document JAF12.9 for the Working Group’s Terms of Reference) and to prepare this Strategy Paper. The Meeting was hosted by the Government of the Republic of Cameroon under the direction of the Honourable Prime Minister of the Republic of Cameroon, Mr. Ephraim Inoni, and co-facilitated by the Ministry of Health of Cameroon, APOC Management and the WHO/Cameroon. Mr. Urbain Olanguena Awono, the Minister of Public Health of Cameroon, was elected chair of the meeting. The Meeting was organized into four main sessions, each representing one or more of the main recommendations put forward by the Working Group in their Strategy Paper, as well as an opening and closing ceremony. The four main sessions were as follows: i) The potential expansion of APOC activities beyond the year 2010 and the strengthening of its mandate and capacity ii) The potential role for APOC in promoting integration of CDTI with primary health infrastructure and the co-implementation of onchocerciasis and other health interventions iii) The potential expansion of the geographic mandate of APOC to former Onchocerciasis Control Program (OCP) countries iv) A proposed Strategic Plan for APOC for 2007-2015 and the future financing needs for APOC The following report summarizes highlights of the opening ceremony, provides a summary of the main discussion points and findings of each main session, restates the declarations made by the Ministers of Health and the Partners during the closing session, and provides information on key documents related to this meeting. JAF12.10 Page 2 SUMMARY OF SESSIONS Opening Session: APOC at a Crossroads During the opening session, meeting participants were treated to a screening of a film entitled “Les Passeurs du Lumière”, which profiled the challenges and achievements of onchocerciasis control. This movie was a co-production of the Mectizan Donation Program, APOC, and the IRD. After a welcoming remark by the Government Delegate of the city of Yaoundé, participants were addressed by the Director of APOC, Dr. Uche Amazigo, who underscored the historic nature of the Meeting. Dr. Amazigo stated that never before had so many Partners assembled in the same room to celebrate the achievements of APOC and the Onchocerciasis Control Programme in West Africa (OCP) and to discuss options to safeguard the investments made in both programs. She noted that although onchocerciasis is a disabling disease with catastrophic consequences, due to assistance from APOC and OCP, onchocerciasis control programs have been put in place by many countries in some of the hardest to reach communities. These programs have boosted agriculture, empowered communities, and strengthened health systems. She emphasized that the success of OCP and APOC was the result of unwavering and long-standing support from the donor community and the Partners. She paid special tribute to the many important donors of APOC and welcomed the presence of representatives of former OCP countries. Since the closure of OCP, many of these countries have shown that sustainable onchocerciasis control is achievable. She highlighted key challenges currently facing APOC, including how to continue to deliver CDTI in turbulent political environments, how to secure sustainable financing, how to sustain high levels of leadership and commitment for onchocerciasis at the national-level, and how could APOCs unique strategy be used to delivery additional health interventions. Dr Ousmane Bangoura of the World Bank, on behalf of the Committee of the Sponsoring Agencies (CSA) thanks the Government of the Republic of Cameroon for hosting the summit. He indicated that APOC is moving toward the achievement of its objective but for reasons beyond its control, about one-third of the projects will not be sustainable by the original deadline of 2010. This delay is due to the impact of conflict and co-endemicity of onchocerciasis and Loa-loa. Consequently, the CSA endorsed the recommendations of the External Evaluation of APOC to extend the life of the Programme beyond 2010. The CSA also stressed the importance of country ownership of projects both in a financial and an organizational sense. Dr. Frédéric Goyet, the current President of the JAF, spoke of how APOC is currently at a crossroads and suggested that while APOC is an exemplary program, well known around the world for its successes, it has also had the courage to ask for an external evaluation that has raised important questions about its future. He was hopeful that the discussion during the Meeting would be helpful to re-launch the discussion about the future of onchocerciasis control. Dr. Paul Samson Lusamba-Dikassa from WHO/AFRO acknowledged the successes achieved thus far with APOC, in terms of pioneering CDTI but also in terms of other JAF12.10 Page 3 innovations, such as those pertaining to monitoring and evaluation, and strengthening health systems. He thanked the donors, but in particular the generous in-kind donation of Merck & Co. He agreed in principle that the APOC trust fund could be used to support onchocerciasis control programs to 2015. Mr. Ephraim Inoni expressed sincere gratitude to all Partners for their participation with this meeting and the work done thus far for onchocerciasis control. He highlighted some of the successes achieved by the onchocerciasis control program in Cameroon, but suggested that in most countries a number of challenges remained to make onchocerciasis control sustainable, including making local funds available. He appealed for greater political will from African countries. Mr. Lionel Laplace of Merck & Co. expressed support for the main recommendations of the Working Group’s Strategy Paper, including the extension of APOC beyond 2010, the expansion of the program to ex-OCP countries, and an increased mandate for APOC to support integrated onchocerciasis control with additional health interventions, in particular lymphatic filariasis. He then reaffirmed Merck & Co.’s commitment to provide Mectizan for as long as is needed. Dr. Adrian Hopkins, representative of the NGDO group, informed the participants that most of the NGDO group’s founding members are still active in onchocerciasis control, but that the group has also grown over the years. Dr. Hopkins highlighted the important contributions made by the NGDO group members, who have contributed at least 25% of the cost of onchocerciasis control activities either through in-kind or financial contributions. He stated that the NGDO group believed that integration would be essential to the future of onchocerciasis control and that there was a need to extend the life of APOC beyond 2010. Mrs. Catherine Hodgkin, Chair of the Working Group, provided a summary of the approach and activities of the Working Group and presented the main recommendations made by the Group in their Strategy Paper. The main recommendations were: Recommendation 1: APOC’s main objective of establishing sustainable national onchocerciasis programmes in all countries where needed should be maintained and endorsed. Recommendation 2: APOC operations should be extended to 2015 to enable it to fulfill its original objectives. • APOC should complete the establishment of CDTI projects in all countries; • APOC should develop an exit strategy which includes effective long-term support mechanisms for countries including mechanisms to provide the limited support to CDTI and onchocerciasis surveillance that will remain necessary after the programme has come to an end. Recommendation 3: APOC should take on the additional objective of developing the evidence base to determine when and where ivermectin treatment can be stopped, and provide guidance to countries on how to prepare for and evaluate cessation of treatment. JAF12.10 Page 4 • The JAF is asked to endorse this new objective recognizing that at present there is insufficient knowledge about when and how mass treatment can be stopped; • APOC should develop a plan, including the excluding resource requirements, to monitor progress in selected areas where cessation of ivermectin treatment has occurred. Recommendation 4: APOC should promote integration and co-implementation of interventions with CDTI to effectively provide multiple health benefits to large populations. • APOC should advocate for integration of CDTI into strengthened health systems; • APOC should develop plans for facilitation, advocacy, and exchange of best practices; • The CSA and the APOC Partnership should encourage joint financing and advocacy for Neglected Tropical Disease (NTD) partnerships; • APOC, TDR, and partners should continue and strengthen operational research on co-implementation; • The CSA should invite other NTD partnership representatives to JAF to promote harmonization of partnerships. Recommendation 5: APOC’s mandate should be extended to include all onchocerciasis endemic countries in Africa where the epidemiological situation requires sustainable CDTI. • The JAF is recommended to endorse this extended mandate which can be executed within the terms of the existing Memorandum; • APOC will thus ensure continuity of support to Special Intervention Zones (SIZ) and former OCP countries where sustainable CDTI still needs to be established; • APOC partners should, promote actions to strengthen the capacity of the MDSC to fulfill its anticipated role in relation to onchocerciasis surveillance. Recommendation 6: Financial planning and fundraising for onchocerciasis control should build on existing mechanisms and traditional donors but should also explore new funding opportunities particularly those offered in the context of NTDs. • Financial planning and fundraising will need to take into account the need to secure country commitments to stable funding for sustainable country programmes; • Financial planning and fundraising should cover the essential activities of the extension to 2015 to allow APOC to fulfill its core mandate and the additional activities identified in the strategic overview; • Planning for an exit strategy should include costing of core regional functions that will be necessary post-APOC together with an overview of which partners and actors may be able to take on these functions and the necessary resource requirements. JAF12.10 Page 5 Session 1: The potential expansion of APOC activities beyond the year 2010 and the strengthening of its mandate and capacity In the Strategy Paper, the Working Group recommended that APOC’s main strategy of establishing sustainable national onchocerciasis control programs in all countries where needed should be endorsed (Recommendation 1) and also that APOC’s operations should be extended to the year 2015 to enable it to achieve this mandate (Recommendation 2). The rationale provided by the Working Group for the extension included the impact of conflict in a number of APOC countries and the consequences of co-endemicity of onchocerciasis with loaisis, which have delayed the establishment of APOC projects in a number of countries. While many APOC countries are on target to achieve sustainable national onchocerciasis programs by the original timeline, the Working Group felt that due to issues beyond the control of APOC, more time would be necessary to fully achieve APOC’s mandate. To motivate discussion among the Partners on the recommended extension of the mandate Dr. Mounkaila Noma, presented a brief summary of the status of onchocerciasis control in APOC countries and Dr. Hans Remme, on behalf of the World Health Organization’s (WHO) TDR provided a summary of a recent research project funded by the Bill & Melinda Gates Foundation, on the question of when and where ivermectin treatment could be stopped. A number of the key discussion elements arose during this session. Since many of the discussion points pertained more closely to the main topic in other sessions, only the main discussion elements related to the extension are included in this section. The main discussion elements during this session were: The Partners agreed that both the OCP and APOC programmes have achieved high levels of success and that this success was largely the result of an effective Partnership (NGDOs, Merck & Co., Ministries of Health, Country Coordinators, Donor Community, and others). However, conflict and co-endemicity of onchocerciasis with loaisis have presented challenges to achieving the original APOC timelines and thus not all APOC projects will be sustainable by 2015. Many countries, including the Democratic Republic of Congo and Cameroon shared some of their own country experiences in dealing with these problems. The Partners discussed how changes in the national, international health, and international development policies have led to a dramatically different environment than the context that existed when APOC was established. The Partners discussed how new opportunities have arisen for APOC to participate with other national and international efforts to address other diseases, in particular neglected tropical diseases, and to reduce poverty through the Millennium Development Goals (MDGs). Dr. Remme provided encouraging results on the potential of being able to effectively control onchocerciasis, in certain countries and under certain conditions, using CDTI. The Partners acknowledged the importance of continued important operational research on onchocerciasis, in particular the JAF12.10 Page 6 question of when and where ivermectin treatment could be stopped. They highlighted the important role that APOC played in helping to better understand the process of treating onchocerciasis. At least one representative of the donor community was concerned that extending the mandate of APOC may require a renegotiation and amendment of the memorandum of understanding of APOC. The legal counsel of the WHO was requested to discuss with The World Bank legal office and advise the JAF on this subject in December 2006. A number of donors were concerned about the financial implications of such an extension. The Director of APOC, however, indicated that this topic would be covered in greater detail during the fourth session on financing. To summarize, the discussion about a potential extension of APOC was rich and fruitful. While the Partners expressed a general feeling of satisfaction with the progress that APOC had made to date, due to unforeseen problems, most also agreed that APOC would not be able to fulfill its mandate by 2010 and thus were in support of an extension of the mandate to 2015. Some concerns were raised about the financial and operational implications of such a decision, and although some of these issues were further clarified in later sessions, the group did request that further clarification on these issues be presented to the JAF. Specifically, during the closing ceremony, Ms. Berard, the representative from Canada and on behalf of the donors, requested detailed operational plans and evidence of country contributions by APOC countries to onchocerciasis control to be presented at the December JAF meeting. The urgent need for more operational research on CDTI was also highlighted, in particular on the question of where and when treatment with ivermectin could be stopped. JAF12.10 Page 7 Session 2: The potential role for APOC in promoting integration of CDTI with primary health infrastructure and the co-implementation of onchocerciasis and other health interventions The effective integration of disease control initiatives into primary health infrastructure as well as the co-implementation of onchocerciasis control with additional health interventions has received a great deal of attention in the international health arena in recent years. As such, the JAF and the CSA had requested some guidance on this issue from the Working Group. The Working Group analyzed the changing context of neglected disease control and recommended that APOC should explore opportunities for both integration and co-implementation (Recommendation 4). Two presentations were made to the Partners to better inform the discussion on integration. Dr. Takougang from Cameroon summarized the findings of an on-going joint APOC/TDR multi-country research study on the feasibility of co-implementing additional health interventions with onchocerciasis control by building on the CDTI. Dr. Dirk Engels of the World Health Organization (WHO) provided an overview of soon to be released protocol developed by the WHO on the co-implementation of mass chemotherapy for helminthic infections, as well as other diseases, in particular trachoma. The following is a brief summary of some of the main discussion elements raised based on the Working Groups recommendations on integration and co- implementation: The Partners noted that further integration into primary health structures as essential to sustainable onchocerciasis control. They also acknowledged that the co-implementation of onchocerciasis with other health interventions might provide new opportunities to increase the visibility, the financial resources, and the sustainability of onchocerciasis control. The inclusion of onchocerciasis control activities into the annual health budgeting process at country level was seen as an important step in the integration of onchocerciasis into health systems. But it was emphasized that this is only one step in the process and that there was a need for greater country leadership on onchocerciasis control and regular allocation of funds to onchocerciasis control activities. Dr. Takougang’s research indicated that the co-implementation of other health interventions with CDTI in an experimental setting did not lead to any detrimental effect on treatment coverage rates for onchocerciasis. The co- implementation, however, did lead to very favorable increases in the coverage of the additional interventions, including the distribution of treated bed-nets and vitamin A supplementation, demonstrating the strength of potentially using the CDTI platform to deliver additional health benefits. The favourable cost-effectiveness of onchocerciasis control was discussed in comparison with other public health interventions. It was noted the cost- JAF12.10 Page 8 effectiveness of onchocerciasis could be further enhanced through co- implementation. This could make onchocerciasis control even more appealing to donors. Dr. Kumaresan, from the International Trachoma Initiative, made the point that HIV/AIDS, Malaria, and Tuberculosis should be seen as an example for onchocerciasis and other neglected tropical diseases. By joining forces, these disease control communities have managed to greatly raise the profile of all three diseases and have greatly enlarge financial resources available for each disease individually. Dr. Fenwick, from the Schistosomiasis Control Initiative, brought to the attention of the Meeting participants of some new funding opportunities for co- implemented interventions primarily at country level, thanks to a major new grant $100 million over 5 years awarded to a new partnership for integrated neglected disease control. The Partners acknowledged that a key challenge to co-implementation would be bringing together the diverse partners involved in the various disease control initiatives. Strong country leadership will however play a key role in championing and implementing these efforts. It was discussed that while APOC could play a role as a driver of this process, co-implementation will require sustained financial support from the international neglected tropical disease community and countries themselves. Another key challenge that was identified was that while it is relatively straightforward to consider the co-implementation of chemotherapy it is also important to realize that co-implementation is complicated in practice by complex patterns of prevalence and different treatment approaches. It is also important to further investigate the feasibility of co-implementation of some of additional aspects of the disease control programs (e.g. education and hygiene) The demand for incentives by community distributors was raised as a potential challenge to co-implementation. The need for more operational research on this topic was raised. The Director of APOC informed the Partners that a research project is now underway to better evaluate these dynamics. In summary, there was a general feeling of optimism among the Partners of the opportunities for further integration of onchocerciasis into primary health infrastructure and for the prospects of co-implementation with other health interventions. They encouraged APOC to continue to explore further opportunities but highlighted the need for more research on the most effective strategies and the implications to onchocerciasis control. They encouraged countries to also take more leadership on this issue. JAF12.10 Page 9 Session 3: The potential expansion of the geographic mandate of APOC to former Onchocerciasis Control Program (OCP) countries As per their terms of reference, the Working Group was asked to reflect upon a possible extension of APOC’s geographical mandate, to include those countries formerly covered by OCP. In their Strategy Paper, the Working Group recommended the endorsement of APOC’s main strategy of establishing sustainable national onchocerciasis control programs in all countries where needed (Recommendation 1) and also that APOC’s operations be expanded geographically to include all onchocerciasis endemic countries in Africa (Recommendation 5). During its operations, OCP achieved unprecedented success in several countries including Burkina Faso, Mali, Senegal, Guinea and Niger. Today these nations continue to maintain the legacy of OCP, but other former OCP countries such as Sierra Leone and Cote d’Ivoire have experienced serious programme setbacks, often resulting from political upheaval and conflict. Recrudescence of disease in former OCP countries unable to sustain disease control activities threatens to undermine the achievements of both OCP and APOC programmes. In light of Recommendations 1 and 5 made by the Working Group, the issue of geographic expansion of APOC was addressed first by a presentation underscoring the role of long-term surveillance in sustaining the achievements of OCP. The issue of surveillance in former OCP countries is one inextricably linked to a question of APOC’s geographic mandate. One player in long-term surveillance has been the Multi Disease Surveillance Center (MDSC), whose activities regarding onchocerciasis control were presented by Dr. Laurent Toé, representing the MDSC Director. This presentation was accompanied by an overview of the current situation regarding onchocerciasis control in the former OCP countries, delivered by Dr. Laurent Yaméogo of APOC. Following the two presentations, the floor was opened for discussion. Several important issues emerged during the presentations and were subsequently discussed by the participants. They are summarized below: The Partners agreed that, for the purposes of surveillance and control activities, a geographical expansion of APOC might be a means of sustaining past achievements and ensuring future successes. One view expressed on the matter stated that an expansion of APOC to include former OCP countries would not be viewed as a step backward but rather as a step forward, allowing a pan- African onchocerciasis control effort to emerge. All endemic countries could then be able to call on APOC for technical assistance on an as-needed basis. Governments were called upon to commit themselves to strengthen surveillance activities in all onchocerciasis-endemic countries, in an effort to avoid spillover into neighboring countries with onchocerciasis-freed zones. Country representatives asked that additional support be given for surveillance and control efforts in those countries in which such activities have been impeded due to conflict. Without such support, surrounding countries where the disease has been effectively eliminated may be endangered by recrudescence. JAF12.10 Page 10 The influx of refugees from endemic to onchocerciasis-free areas was of concern to countries, as this problem raised the spectre of disease recrudescence. Support for evidence-based research activities, by the MDSC and other players, was called for to ensure the quality of data and appropriate interpretation of results for subsequent control efforts. Similarly, continuation of APOC’s monitoring and evaluation activities were suggested as a means of benchmarking progress on these fronts. The activities of the MDSC were discussed in some depth. Participants suggested that its role be clarified by WHO/AFRO. Additionally, the Partners discussed strengthening its capacity, namely to make operative its activities in all 11 of the former OCP countries. The success of the Special Intervention Zones (SIZs) was brought to light in some regions, with a call for additional support of these activities. A suggestion was made for APOC to develop a series of best practices in what has accomplished thus far, and for this knowledge to be shared. The question of cross-border activities, especially with regard to surveillance, was discussed. The MDSC was suggested as a vehicle for cross-border surveillance, as was the West African Health Organization. The issue of cross- border activities was raised in particular by the representatives of countries that had effectively eradicated the disease but whose borders were shared with nations where programmes had experienced setbacks. A suggestion was made for WHO/AFRO to clarify APOC’s role in the extension of geographical activities so as to minimize conflicts in organizational structure and to ensure that duplication of operations does not arise. At the conclusion of the session and its discussion, a consensus was reached concerning the geographical expansion of APOC’s activities to include former OCP nations. Participants, particularly Ministers and other representatives of participating governments, had expressed a fear that without a geographical expansion of activities, onchocerciasis achievements would suffer setbacks. They stressed that the vector knew no constraints concerning national borders and that disease recrudescence in some regions could undermine both OCP’s and APOC’s achievements to date. Special attention was paid to the role of long-term surveillance and cross-border activities, and ideas were put forward on what bodies could potentially facilitate such activities. Participants made a call for further assistance particularly in the area of long-term surveillance. Concern was raised over the clarification of roles of APOC, the MDSC and WHO/AFRO in the geographical extension of activities. Finally, Claude Vignes of WHO Legal pointed out that the Partners had no legal powers of decision-making regarding the geographical extension. A recommendation made herein would be submitted to the governing body of APOC, the Joint Action Forum JAF12.10 Page 11 (JAF), which is entitled to make a final decision regarding geographical expansion of APOC’s mandate. JAF12.10 Page 12 Session 4: A proposed Strategic Plan for APOC for 2007-2015 and the future financing needs of APOC In their Strategy Paper, the Working Group recommended financing the extension of APOC until 2015 as per the time extension and geographical expansion of the mandate, to help facilitate long-term surveillance and support for countries post- APOC (Recommendation 6). A discussion of financing mechanisms was taken up initially in comments made by Dr. O.K. Pannenborg of the World Bank at the start of the third session and later expanded upon in the fourth session in presentations made by Dr. Amazigo of APOC and Dr. Bangoura of the CSA. Dr. Amazigo presented an APOC exit strategy and preliminary budget for activities from 2007 to 2015. APOC management proposed dates of withdrawal of Trust Fund support from stable and fragile states. Dr. Bangoura gave an overview of the financing currently available and projected from donors, and preliminary data from countries, NGDOs, and Merck & Co. The proposed additional budget of 39 million dollars covered extended and expanded activities to take place between 2007 and 2015, as well as provisions for co- implementation of disease interventions, capacity development and operational research on when and where to stop treatment. An appeal was made to all Partners to renew their financial commitments in order to protect control efforts thus far. Several important issues emerged during the presentations and were subsequently discussed by the participants. They are summarized below: Mr. Pannenborg expressed the view that the onchocerciasis control efforts were seen in the international community as owned first and foremost by the governments of Africa and their Ministers of Health. He urged Ministers of Health to engage with their Ministers of Finance in an effort to make onchocerciasis control programmes sustainable. He stressed that such inter- ministerial negotiations are not easy and suggested that the Bank act as a facilitator in this process. He also underscored the link between onchocerciasis control and the MDGs, specifically with the education sector, and pointed to the special trust funds to increase school enrolment. He stated that the Bank stood ready to continue its funding of APOC activities until 2010 as agreed upon, but was open to discussions on how to support the programme up to 2015 and beyond. He suggested an exploration of innovative funding mechanisms and other modalities of direct and indirect financing such as catalytic funding and conditional cash transfers. Critical impediments to financing of onchocerciasis control programmes mentioned by the participants included delays in financial flow, chronic under- funding of the health sector and delays in the release by governments of counterpart funding. Fragile states have also had difficulty raising the necessary funds to make their contribution to the control efforts. Countries reported some difficulty with the vertical financial reporting system of WHO/APOC. Dr. Amazigo stressed the importance of a system to track the funds and proposed plans to train national coordinators in financial management and in proper documentation of finances. Countries were urged to develop financial sustainability plans and to communicate with the Ministers of Finance to increase contributions from the JAF12.10 Page 13 government budget and to progressively integrate the costs of onchocerciasis into health sector policy and priority financing plans. Dr. Bangoura’s presentation suggested a mainstreaming of onchocerciasis control into public sector management instruments via SWAPS, HIPC, PRSPs and PEF. Furthermore, he indicated that onchocerciasis be included in sub- national budgets and priorities, and that onchocerciasis control be linked with country projects and programmes supported by WHO, the World Bank, the African Development Bank, bilateral partners, NGDOs and the Global Fund. During the closing ceremony, the Donors requested that each country present at the upcoming JAF detailed operational plans with details on indicators to be achieved, an analysis of the potential risks to progress, a clarification of the roles and responsibilities of APOC with regards to the countries, a detailed budget, and a strategy that will enable the donors to act. In addition, they requested at the upcoming JAF, and at future JAF meetings, each country should prepared annual progress reports outlining steps taken to make onchocerciasis a priority and evidence of financial allocations made to onchocerciasis. Discussion was raised surrounding the budget estimates, namely that the figures were static and did not take into account the dynamic nature of the social, political and financial contexts in which onchocerciasis control was being carried out. Increased advocacy was called upon to raise additional funds and to mobilize resources. The inclusion of onchocerciasis control efforts, particularly with lymphatic filariasis and trachoma, was suggested as a means of drawing greater attention and resources to the NTD agenda. Following the conclusion of the discussion, financial commitments were reaffirmed by Saudi Arabia who stood ready to discuss the financial implications of an extension of time and an expansion of the geographical mandate. In summary, participants agreed that financial sustainability was a core principle of onchocerciasis control. A renewed financial commitment by the Partners and innovative mechanisms for generating funds were both necessary as a means to achieve sustainability at the national level. Countries were urged to open lines of communication between Ministers of Health and Finance, with the Bank offering to facilitate this process. Furthermore, countries were advised to integrate onchocerciasis control into public sector management and priorities at the sub- national level and to improve upon their financial reporting systems. Finally, a coordination and harmonization of the NTD programmes to develop a more unified and coordinated agenda was suggested as a way to increase advocacy and funds, through which the various NTDs would stand to benefit, fiscally and otherwise. JAF12.10 Page 14 Closing Ceremony: Generating consensus statements on the future of onchocerciasis control After a closed-door session of the African Ministers, all of the meeting participants re- assembled for a final discussion and to make two important declarations on the future of onchocerciasis control. First, many of the meeting participants thanked the Chair of the meeting, the Prime Minister of the Republic of Cameroon, the hosts of the meeting, the attendees, the presenters, the Working Group members, as well as APOC management for a productive meeting. There was a general feeling that the meeting had achieved its goals and all of the discussion sessions had been useful. In addition, the participants thanked the hosts for the excellent hospitality they received during their visit to the Republic of Cameroon. Second, the Minister of Health of Tanzania extended a warm invitation to all invitees to the upcoming JAF meeting, which is scheduled to be held 5-8 December 2006 at the White Sands Hotel in Tanzania. More information is available on the following website: www.moh.go.tz. Third, two declarations were made during the closing ceremony. The text of both of these declarations can be found in the next section of this report. The Ministers of Health prepared and agreed to an important declaration on onchocerciasis control in Africa. The declaration highlighted the important contributions of APOC and OCP and expressed a renewed commitment to work towards the elimination of onchocerciasis in all countries where it is a public health problem. In addition, all meeting participants agreed in principle to a declaration made in response to the six recommendations made the Working Group. After some important additions by the donors, the meeting participants agreed in principle with the main recommendations of the Working Group. Finally, the Chair of the meeting expressed special thanks to all of those who had helped to make this meeting a success, including the participants. He stated that he felt that the meeting had been hugely successful, that it has met all of its objectives, and that it had been successful in building momentum that will be necessary for APOC to continue to help free the millions of affected people in Africa from the burden of onchocerciasis. JAF12.10 Page 15 SUMMARY OF DECLARATIONS 1. Ministers’ Declaration: Yaoundé Declaration on Onchocerciasis Control in Africa We, the African ministers of health, participating in the Special Summit of Partners of the African Programme for Onchocerciasis Control held in Yaounde, Cameroon, from 26 to 27 September 2006, to discuss the future of river blindness (onchocerciasis) in Africa, Considering onchocerciasis as a major cause of poverty; Concerned that, in spite of the efforts of the African Programme for Onchocerciasis Control (APOC), and before it, those of the Onchocerciasis Control Programme (OCP), over 120 million people in 19 countries still face the threat of river blindness; Acknowledging that one obstacle standing in the way of successful onchocerciasis control has been the negative impact of conflicts in a number of APOC and ex OCP countries; Recognizing that the movement of human populations and frequent social and political upheavals in the African Region have greatly increased the risk of transmission and/or re-emergence of onchocerciasis; Concerned about the risk that more than US$ 1.5 billion already invested by donors, the countries and their development partners could be lost; Noting the efficiency of APOC interventions; Convinced that integration and joint implementation of community-directed treatment with ivermectin (CDTI) with other health interventions will effectively provide many health benefits to remote populations; Mindful of the urgent need for a macrofilaricide with a view to accelerate progress towards the elimination of onchocerciasis in all countries; 1. EXPRESS our commitment to work together to accelerate the elimination of river blindness as a public health and socio-economic development problem in all countries; 2. Call for the intensification of control activities and surveillance in post- conflict countries and countries with pockets of co-endemicity of onchocerciasis and loiasis (tropical eye worm); JAF12.10 Page 16 3. ENDORSE the conclusions of the working group on the future of APOC and its recommendations to extend the life of APOC to 2015 and enlarge its activities to ex-OCP countries; 4. Affirm country leadership and recommend the establishment of national sustainable CDTI programmes in all onchocerciasis endemic countries of the Region; 5 Urge endemic countries to make annual budgetary commitment for onchocerciasis control activities as part of PRSP and in line with MDGs; 6. APPRECIATE the long-standing commitment of donors and NGDOs to onchocerciasis control and the pledge of Merck to continue providing ivermectin (Mectizan®) for as long as they are needed; 7. REQUEST donors and development partners to support MACROFIL research and onchocerciasis surveillance; 8. RECOMMEND strongly that APOC provide a scientific evidence base to determine the steps, the period and the area where ivermectin treatment could be stopped in close consultation with affected countries; 9. INVITE all those who share our commitment to subscribe to the present declaration. Done in Yaounde this twenty-seventh day of September in the year of two thousand and six 2. Partners’ Declaration: During the Special Meeting of the African Programme for Onchocerciasis Control (APOC), 26-27 September 2006, the participants developed a broad consensus on the Strategic Overview of the Future of Onchocerciasis Control in Africa report presented by the Working Group and makes the following recommendations to Joint Action Forum (JAF): Recommendation 1: The Partners recognize the achievements of APOC and OCP and endorse again that its main objective is to eliminate onchocerciasis as a public health problem and build sustainable national onchocerciasis control in all countries where needed. The Partners emphasize the importance of the Partnership and the unique contributions made by countries, bilateral and multinational donors, the NGDOs, and Merck, as well as those made at the program and country level. Recommendation 2: Due to unforeseen issues, the Partners believe that APOC will be unable to fully achieve its mandate if it were to end operations as scheduled in 2010. The Partners agree in principle that APOC’s mandate should be extended to 2015 and its operations strengthened. APOC should continue to work to build sustainable JAF12.10 Page 17 national programs and continue to develop an exit strategy that will enable it to achieve its expanded mandate and secure post-APOC sustainability. Recommendation 3: The Partners recognize the importance of operational research in developing and sustaining effective national onchocerciasis control programs. The Partners recognize the need to develop the evidence base to determine how and when treatment with ivermectin can and should be stopped. Recommendation 4: The Partners agree that APOC should actively pursue and promote integration of onchocerciasis control into health systems and explore opportunities to promote cooperation at international and national levels with other disease control initiatives and the co-implementation of CDTI with other health interventions at the community and district levels. APOC should become a key advocate for integrated onchocerciasis control in the framework of Neglected Tropical Disease control. Recommendation 5: The Partners recognize the need to provide support to all areas in Africa that are meso- or hyperendemic for onchocerciasis. The goal of APOC is to assist in the elimination of onchocerciasis as a public health problem throughout the continent, which will require special attention paid to cross-border issues, to knowledge management, and a need to build country-level sustainable surveillance capacity supported by regional actors. The Partners request clarification concerning the respective role of APOC, WHO/AFRO, MDSC and the countries in onchocerciasis surveillance. Recommendation 6: The Partners recognize that the extended timeframe and mandate of APOC may require additional financing. The Partners agree in principle to extend the existing trust fund arrangement, possibly adjust current cost-sharing arrangements. This may include exploring new sources of funds such as those available for Neglected Tropical Diseases. The Partners are optimistic that the level of funds required by the proposed draft action could be mobilized. Achieving this challenge will require detailed planning, effective advocacy, country leadership and increased financial commitment at country level. JAF12.10 Page 18 APPENDIX List of Participants PAYS/COUNTRIES 06.10.2006 Angola 1. Dr Antonio José PEDRO, Coordonnateur National du Programme National de Lutte contre l’Onchocercose, s/c C.P. 3243, Rua 1 Congresso do MPLA 67, Luanda, Angola. Tel : 0044 222 39 67 22 – Fax : 0044 222 39 67 22 – E-mail oncocercose@snet.com.ao Burundi 2. Dr Triphonie NKURUNZIZA, Ministre de la Santé, Ministère de la Santé publique, B.P. 1450, Bujumbura, Burundi Fax : (257) 22 91 96 – E-mail :triphonie20022000@yahoo.fr 3. Dr Norbert BIRINTANYA, Coordonnateur National du Programme National de Lutte contre l’Onchocercose, B.P. 1820, Bujumbura, Burundi Tel : (257) 249 334/7 32 134/942358 – Fax : (257) 22 9196 – E-mail: birintanya@yahoo.fr Cameroun/Cameroon 4. M. Urbain OLANGUENA AWONO, Ministre de la Santé publique, Ministère de la Santé publique, B.P. 155, Yaoundé, Cameroun Tel : (237) 222 0172 - Fax : (237) 222 02 33 5. Dr Hélène MAMBU MA DISU, Représentant de l’OMS au Cameroun, B.P. 155, Yaoundé Tel : (237) 221 10 78/221 1003 - Fax : (237) 221 1077 - E-mail : mambuh@cm.afro.who.int 6. Professeur Assumpta Françoise Lucienne BELLA, Directeur de la Lutte contre la Maladie, Président du GTNO, Ministère de la Santé publique, Yaoundé Tel : (237) 996 52 86 – Cellulaire : (237) 223 93 48 – Fax : (237) 222 44 19 - E-mail : ngonbidjoe@yahoo.fr 7. Dr Joseph KAMGNO, Conseiller Technique, Loase Cameroun, Ministère de la Santé, B.P. 1274, Yaoundé, Cameroun Tel : (237) 778 97 36 – Fax : (237) 223 15 64 – E-mail :kamgno@pasteur-yaounde.org 8. Dr Marcelline NTEP, Coordonnateur National du Programme National de Lutte contre l’Onchocercose, Ministère de la Santé publique Tel : (237) 222 69 10 – Fax : (237) 222 69 10 – E-mail : sgoa@camnet.cm JAF12.10 Page 19 9. Dr Albert EYAMBA, Country Director, The Carter Center, P.O. Box 5764, Yaounde, Cameroon Tel/Fax: (237) 221 73 26– E-mail : carter_center@creolink.net ou Italbert@creolink.net 10. Dr Rosa BEFIDI-MENGUE, Country Representative, Sight Savers International (SSI), P.O. Box 4484, Yaounde, Cameroon, Tel: (237) (237) 221 12 33, Mobile: (237) 760 43 06, Fax: (237) 221 79 43, E-mail: rbefidi@ssi-cameroon.org or ydeoffice@ssi- cameroon.org 11. Prof. Louis-Albert TCHUEM TCHUENTE, Coordinator, National Control of Schistosomiasis and STH, Director, Centre for Schistosomiasis and Parasitology, P.O. Box 7244, Yaounde, Cameroon Tel: (237) 221 01 83 (office)/(237) 991 18 09 (Mobile) - Fax: (237) 221 50 77 - E-mail: tchuemtchuente@schisto.com 12. Mr Georges MBENDA BEHALAL, Directeur Exécutif, Perspective (PP) , B.P. 6842, Yaoundé, Cameroun Tel : (237 223 77 72 – Fax : (237) 223 77 72/933 62 22 – E-mail : info_perspective@yahoo.fr 13. Dr Zakariou NJOUMEMI, Economiste de la Faculté, Health Economic Research and Evaluation Group (HEREG), B.P. 8119, Yaoundé 8, Cameroun Tel: (237) 201 91 71/784 47 44 14. Madame Julie AKAME, Coordonnatrice provinciale Oncho du Centre, Yaoundé, Cameroun Tel : (237) 770 93 02 - E-mail : julak26@yahoo.fr 15. Madame Josette ESSAMA, Point Focal, Filariose Lymphatique, Yaoundé, Cameroun Tel/Cel: (237) 742 27 73 16. Madame Georgette NDONGMO, Secrétaire au Programme VIH/SIDA, OMS Cameroun Tel : (237) 221 20 80/81 et (237) 961 02 85 – Fax : (237) 221 10 77 – E-mail : gdifes@yahoo.fr; ndogmog.who.cm.int 17. Dr Martina BAYE LUKONG, Chef de Division et de la Coopération, Ministère de la Santé publique, s/c OMS B.P. 155, Yaoundé, Cameroun Tel : (237) 798 65 65 18. Madame Myriam Désirée TAYOU, Assistante Administrative/Carter Center, Yaoundé, Cameroun Tel : (237) 221 73 26 et (237) 964 13 06 – Fax : (237) 221 73 26- E-mail : myriamkam@yahoo.fr et tayou@creolink.net 19. Mademoiselle Pélagie CHEDJIO TEGANTCHOUANG, Assistante Administrative, Helen Keller International, Yaoundé, Cameroun Tel: (237) 220 97 71 et (237) 735 66 96 – E-mail: ctpelagie@yahoo.fr et cpelagie@hki.org 20. Dr. Jean Arthur MBIDA MBIDA, Coordonnateur TED, B.P. 378, Yaoundé Messa, Cameroun Tel : (237) 994 39 64 et (237) 223 75 74 – E-mail : mbidajean@yahoo.fr et www.yaoundefoundation.org JAF12.10 Page 20 21. Madame Julienne MIMBOUGA, Chef de Section Activités Supplémentaires de Vaccination, GTC/PEV, Yaoundé, Cameroun Tel : (237) 994 53 13 – E-mail : mimbouga@yahoo.fr 22. Monsieur Paul Félicien MESSI, Secrétaire, Secrétariat GTNO/OMS/APOC, Yaoundé, Cameroun Tel : (237) 222 69 10 et (237) 954 30 34 – E-mail : sgoa@camnet.cm; mepapeleoos@yahoo.fr 23. Monsieur Laurent Olivier AMOUGOU, Agent de Liaison, IEF, Yaoundé, Cameroun Tel : (237) 999 67 90 24. Monsieur Michel HENDJI YOYA, Responsable Financier GTNO, Yaoundé, Cameroun Tel : (237) 745 46 26 - Fax : (237) 222 69 10 – E-mail : yoya_michel@yahoo.com 25. Monsieur Modeste AYANMA, Comptable, OMS/Yaoundé, Cameroun Tel : (237) 221 02 51 – Fax : (237) 221 10 77 – E-mail : ayanma@cm.afro.who.int 26. Monsieur Sébastien MANGELE, Assistant Administratif et Financier, OMS/Yaoundé, Cameroun Tel : (237) 997 33 24 - Fax : (237) 221 10 77 – E-mail : mangeles@cm.afro.who.int 27. Monsieur Auguste BASSEGA BA NJEL, Directeur Régional Centre Sud et Est, AES- SONEL, B.P. 151 ,Yaoundé, Cameroun Tel : (237) 750 02 54/(237) 223 59 53 – Fax : (237) 223 77 68 – E-mail : auguste.bassega@aes.com 28. Madame Marie OTTOU MEKA, Chargée d’Etudes Relations Publiques, AES-SONEL, B.P. 151, Yaoundé, Cameroun Tel : (237) 222 19 30/(237) 770 18 65 – E-mail : akoomeka@yahoo.fr 29. Dr Aaron NKWELLE AKEDE, Responsable Médico-Social/Médecin Chef, SONARA LIMBE, B.P. 365, Yaoundé, Cameroun Tel : (237) 333 22 38 – Fax : (237) 333 21 88 – E-mail : ankwelle2000@yahoo.com Congo Brazzaville 30. Dr Alphonse GANDO, Ministre de la Santé et de la Population, Ministère de la Santé et de la Population, B.P. 2101, Brazzaville, République du Congo Tel : (242) 572 56 49 31. Dr François MISSAMOU, Coordonnateur National du PNLO, Secrétaire Exécutif du GTNO, Direction de la lutte contre la Maladie, B.P. 236 ou 1066, Brazzaville, Congo Tel : (242) 668 05 63 – Fax : (242) 81 04 81 – E-mail : opc_congo@yahoo.fr 32. Dr Michel KAB-MBOKO, Conseiller à la Santé, Ministère de la Santé et de la Population, Brazzaville, Congo Tel: (242) 558 18 24 – E-mail: Kaba-mboko@yahoo.fr 33. Mr Henri Félix KOTAOU, Attaché au Matériel et Chargé de Missions du Cabinet du Ministre, Ministère de la Santé et de la Population, Brazzaville, Congo Tel: (242) 622 30 30 – E-mail: kotaoufelix@yahoo.fr JAF12.10 Page 21 Ethiopie/Ethiopia 34. Dr Zerihun TADESSE, A/Head Diseases Prevention and Control Department, Federal Ministry of Health, P.O. Box 1234, Addis-Ababa, Ethiopia Tel: (251) 11 515 09 93– Fax: (251) 111 551 193 66 35. Dr Afework HAILEMARIAM, Head, Malaria & Other Vector Borne Diseases Prevention and Control, Ministry of Health , P.O. Box 1234, Addis-Ababa, Ethiopia Tel: (251) 11 515 09 93– Fax: (251) 111 551 193 66 – E-mail: malaria@ethionet.et or afenwork@yahoo.com 36. Dr Daniel ARGAW, Disease Prevention Control Officer, World Health Organization (WHO), P.O. Box 3069, Addis-Ababa, Ethiopia Tel: (251) 911 25 43 82 – Fax: (251) 11 551 40 37 – E-mail: daniel@et.afro.who.int Gabon 37. Son Excellence Michel YADOUNGOU, Ambassadeur de la République Gabonaise, Ambassade du Gabon, Bastos, B.P. 4130, Yaoundé, Cameroun Tel : (237) 221 43 47 – Fax : (237) 221 43 47 Guinée Equatoriale/Equatorial Guinea 38. Monsieur A.M. NDONG, Ministre de la Santé et du Bien Etre Social, Ministère de la Santé et du Bien Etre Social, Malabo, Guinée Equatoriale Tel : (240) 27 38 15 39. Dr Nsue Anacleto SIMA, Directeur National, Programme de lutte contre l’Onchocercose et autres Filarioses, Ministère de la Santé et du Bien Etre Social, Programme Onchocercose et Autres Filarioses, Malabo, Guinée Equatoriale Tel : (240) 23 26 20 – Fax : (240) 09 32 36 Kenya 40. Dr W. G. MACHAGE, Assistant Minister for Medical Services, Ministry of Health, P.O. Box 45335, Nairobi, Kenya Tel: (254) 722 81 9165 - Fax: (254) 27 25 624 – E-mail: sangdvbd@yahoo.com 41. Dr. David SANG, National Coordinator, Division of Vector Borne Diseases, Ministry of Health, P.O. Box 20750, Nairobi, Kenya Tel: 722819165 – Fax: (254) 27 25 624- E-mail: sangdvbd@yahoo.com Malawi 42. Honourable Aaron SANGALA, Deputy Minister of Health, Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi Tel: (265) 1 788 467 – Fax: (265) 1 750 896 - E-mail: elmaestro@globemw.net 43. Mr Square MKWANDA, Ag National Onchocerciasis Coordinator, Onchocerciasis Control Programme, c/o Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi Tel: (265) 8 30 34 46 or (265) 1 750 896 – Fax: (265) 1 750 896 – E-mail: oncho@malawi.net JAF12.10 Page 22 Mozambique 44. Dr. João Manuel CARVALHO FUMANE, National Coordinator, Nacional Institute of Health, Ministry of Health, Av. Eduardo Mondiane/ Salvador Allende, P.O. Box 264, Maputo, Mozambique Tel: (258) 1 32 71 31 - Fax: (258) 1 43 11 03– E-mail: j.fumane@teledata.mz or j.fuman@tvcabo.co.mz Nigéria/Nigeria 45. Dr. Anthonia NJEPUOME, Director of Public Health, Federal Ministry of Health, Department of Public Heath, Federal Secretariat, Abuja, Nigeria, P.O. 083, Garki – Maitama, Abuja, Nigeria Tel: (234) 80 44 83 926 - Fax: (234) 9 523 4590 – E-mail: ngonjep@yahoo.com 46. Mrs. Patricia OGBU-PEARCE, Acting Coordinator, National Onchocercaisis Task Force (NOTF), Federal Ministry of Health, Federal Shehu Shagari Way, P.O. Box 083, Garki – Maitama, Abuja, Nigeria, Tel: (234) 9 523-7049 – Mobile: (234) 8035613104 - Email :peje2004@yahoo.com République Centrafricaine/Central African Republic 47. Dr Bernard LALA, Ministre de la Santé publique et de la Population, Ministère de la Santé publique et de la Population, B.P. 783, Bangui, République Centrafricaine 48. Dr Georges YAYA, Chef de Service d’Ophtalmologie, Programme National de lutte contre l’Onchocercose, Ministère de la Santé et de la Population, B.P. 783, Bangui, République Centrafricaine Tel : (236) 61.61.17 – Cellulaire : (236) 04.53.08 – Fax : s/c OMS – (236) 61.01.37 République démocratique du Congo/Democratic Republic of Congo 49. Mr François LUAMBO, Chargé d’Affaires a.i., Boulevard URSS/Bastos Tel: (237) 557 96 08 – E-mail/ esiongo@hotmail.com 50. Dr Kupa Marcel MUKENGESHAYI, Coordonnateur National, Programme National de lutte contre l’Onchocercose, Avenue de la Justice No 36, Commune de la Gombe, RDC, Tel : (243) 9999 47 138 – Fax: (234) 12 33 247 - E-mail : mukkupa@yahoo.fr; pnlo_rdc@yahoo.fr Tanzanie/Tanzania 51. Dr. Aisha Omar KIGODA, Deputy Minister of Health, Ministry of Health and Social Welfare, P.O. Box 9083, Dar-es-Salaam, Tanzania Tel: (255) 22 211 3077/(237) 784 416 866 – Fax: (255) 02 2138060 – E-mail: aishakigoda@yahoo.co.uk 52. Dr Grace SAGUTI, National Coordinator, Eye Care Services and Onchocerciasis Control, Ministry of Health and Social Sciences, P.O. Box 9083, Dar-es-Salaam, Tanzania Tel: (255) 22 2130009/(255) 754 28 78 75 – Fax: (255) 22 2130009 – E-mail: gracejengo@yahoo.co.uk or nec_ocp@yahoo.com; gsaguti@yahoo.co.uk JAF12.10 Page 23 Tchad/Chad 53. Madame NGARMBATINA Carmel Sou VI, Ministre de la Santé publique, Ministère de la Santé publique, B.P.440, N’Djaména, Tchad Tél : (235) 51 51 14 ou 28 99 20 -Fax : (235) 51 58 00 – E-mail :odjimbeye@yahoo.fr 54. M. Nadjilar LOKEMLA, Coordonnateur du Programme National de Lutte contre l’Onchocercose, B.P. 4057, N’Djaména, Tchad Tél : (235) 629 01 64 - Fax : (235) 52 48 38 – E-mail :nadjilar@yahoo.fr Ouganda/Uganda 55. Mr. Mohammed KEZAALA, Permanent Secretary, Ministry of Health, Ministry of Health, P.O. Box 7272, Kampala, Uganda (E.A) Tel: (256) 41 340 872 – Fax: (256) 41 231 584 – E-mail: psmoh@infocom.co.ug 56. Dr. Richard NDYOMUGYENYI, National Onchocerciasis Coordinator, P.O. Box 1661, Kampala, Uganda, Tel: (256) 41 348332– Fax: (256) 41 348339 – E-mail: notf@imul.com; notf@vcdmoh.go.ug DONATEURS/DONORS Arabie Saoudite/Saudi Arabia 57. Eng. Hasan M. Al-ATTAS, Director General, Technical Department, The Saudi Fund for Development, Kingdom of Saudi Arabia, P.O. Box 50483, Riyadh 11523 Tel: 4640292/9661 464 1928 - Fax: 464750/966 1464 7450 – E-mail : hattas@sfd.gov.sa 58. Mr. Saud A. Al-FANTOUKH, Director General, Control & Audit Department, The Saudi Fund for Development, Kingdom of Saudi Arabia, P.O. Box 50483, Riyadh 11523 Tel: 4640292/9661 46 40 723 - Fax: 464750/9661 46 47 450 – E-mail : salfantoukh@yahoo.com Banque Mondiale/The World Bank 59. Mr. O. K. PANNENBORG, Senior Advisor, Human Development Africa Regiona, The World Bank, 1818 H Street, NW, Washington DC 20043, USA Tel: (202) 473 4415 – Fax: (202) 473 8216 – E-mail: Opannenborg@worldbank.org 60. Dr Ousmane BANGOURA, Onchocerciasis Unit Coordinator, The World Bank,1818 H Street, NW, Washington D.C 20043, Tél: (202) 373 4004 – Fax: (202) 373 8216 – E- mail: Obangoura@worldbank.org 61. Dr Bernhard LIESE, Public Health Specialist (Consultant), Onchocerciasis Coordination Unit, The World Bank,1818 H Street, NW, Washington DC 20433 Tél: (202) 458 4491 – Fax: (202) 473 8216 – E-mail: Bliese@worldbank.org JAF12.10 Page 24 Belgique/Belgium 62. Dr Jacques Walter LARUELLE, Chargé de Programmes, Ministère des Affaires étrangères, Direction générale de la Coopération au Développement, rue des Petits Carmes 15,– B-1000 Bruxelles, Belgique Tel : (0032) 2 519 07 52 – Fax : (0032) 2 519 05 70 – E-mail : jacques.laruelle@diplobel.fed.be Canada 63. Ms. Catherine BERARD, Second Secretary (Development), Canadian Embassy, P. O. Box 1130 Addis Ababa, Ethiopia, Tel: +251 (0) 11 371 30 22, CELL: +251 (0) 911 20 10 08, Fax: +251 (0) 11 371 30 33, MITNET: 314-3319 – E-mail: catherine.berard@international.gc.ca France 64. Dr Frédéric GOYET, Chef du Bureau de la Santé, Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP, France Tél : 015 369 3186 – Fax : 33 015 369 3719 – E-mail : frederic.goyet@diplomatie.gouv.fr ORGANIZATIONS NON GOUVERNEMENTALES DE DEVELOPPEMENT (ONGD)/NON GOVERNMENTAL DEVELOPMENT ORGANIZATIONS (NGDO) Christoffel Blindenmission (CBM) 65. Dr Adrian Dennis HOPKINS, Medical Advisor, Regional Office, P. O. Box 58004- 00200, Nairobi, Kenya Tél: +254 3751 654/798 – Fax: 254 20 374 0305 - E-mail: ahopkins@cbmi-nbo.org: adrianhopkins@aol.com The Carter Center 66. Dr Albert EYAMBA ITOUMBOU, Country Representative, Yaounde, Cameroon, Tel: 237 221 73 26- Fax: 237 221 73 26 – E-mail: ITAlbert@creolink.net or carter- center@creolink.net 67. Mr Catherine MENTOU TADZONG, Chargé de Programme, Carter Center Yaoundé, B.P. 5763, Cameroun Tel: (237) 221 73 26 – Fax: (237) 221 73 26 – E-mail: cmentou@yahoo.fr Glaxosmithkline (GSK) 68. Mr. Andy WRIGHT, Director, Lymphatic Filariasis Programme, Global Community Partnerships, SmithKline Beecham (SB) GlaxoSmithKline, 980 reat West Road, Floor C12, Brentford, Middlesex, TW8 9GS, United Kingdom Tel: +44 208 047 5515 – Fax: +44 208 047 0684 – E-mail: andy.l.wright@gsk.com JAF12.10 Page 25 Helen Keller International (HKI) 69. Ms Nancy J. HASELOW, Vice-President and Regional Director of Asia Pacific, Helen Keller International, HKI Regional Office, Hanoi, Vietnam Tel: +844-971-2562 - Fax: +844-971-2562 - E-mail: nhaselow@hki.org and nhaselow@hotmail.com 70. Dr Danny HADDAD, Regional Technical Advisor for Eye Health and Onchocerciasis, HKI Regional Office for Africa, Dakar, Senegal Tel: (221) 869 10 63 – Fax: (221) 820 74 77 - E-mail: DHaddad@hki.org 71. Dr Xavier Crespin, Country Representative, HKI Country Director for Cameroon at the Helen Keller International, Cameroon Country Office, P.O. Box 14227, Yaounde, Cameroon, Tel: (237) 220 97 71, Fax: (237) 221 08 48, E-mail: xcrespin@hki.org ou Hkicm.director@creolink.net 72. Dr BROU-Tanoh Adjoba Marie , MD,MPH, Helen Keller international, Country Director, II Plateaux Vallon, Villa 1516, Rue des jardins, 17 BP 1334 Abidjan 17, Côte d'Ivoire International Eye Foundation (IEF) 73. Ms. Victoria SHEFFIELD, Executive Director, International Eye Foundation (IEF), 10801 Connecticut Avenue, Kensington, MD 20895, USA Tel: (240) 290 0263 ext. 14 – Fax: (240) 290 0269 – E-mail: vsheffield@iefusa.org 74. Mr Pierre BALEGUEL NICOT, Managing Director, B.P. 3878, Yaounde, Cameroon Tel: (37) 223 75 74 – Fax: (237) 23 75 74 – E-mail: baleguel2001@yahoo.fr International Trachoma Initiative 75. Mr. Jacob KUMARESAN, President, International Trachoma Initiative, 441 Lexington avenue, Suite 1101, New York, NY 10017, USA Tel: (212) 490 6460 – Fax: (212) 490 6461 – E-mail: jkumaresan@trachoma.org 76. Mr. Ibrahim JABR, Vice President Programs, International Trachoma Initiative 441 Lexington avenue, New York, NY 10017 Tel 1212 490 6460, Fax 1212 490 6461, E-mail: ijabr@trachoma.org Lions Club International Foundation (LCIF) 77. Madame Dominique COSTE, Présidente Commission Sight First Afrique Centrale & Océan Indien, Représentante de la LCIF pour les Programmes de Santé, B.P. 4794, Yaoundé, Cameroun Tel : (237) 220 50 07 – Fax : (237) 221 55 67 – E-mail : sight-first@camnet.cm 78. Dr François LARIVIERE, Représentant de l’IRD au Cameroun, IRD, B.P. 1857, Yaoundé, Cameroun Tel : (27) 220 15 08 – Fax : (237) 220 18 54 – E-mail : François.Riviere@id.fr JAF12.10 Page 26 Mectizan Donation Program 79. Dr Bjorn THYLEFORS, Director, Mectizan Donation Program, 750 Commerce Drive, Decatur, 30030 GA, United States of America Tel: + 1 404 371 1460 – Fax: +1 404 371 1138- E-mail: bthylefors@taskforce.org Merck and Co, Inc. 80. Mr Lionel LAPLACE, Africa HIV Manager, Merck Sharp & Dohme Tel/Cell: +33 6 855 271 98, RCI Tel/Fax: + 255 2241 9116, E-mail: lionel_laplace@merck.com 81. Mr Alain Gérôme TATANGMO, Health Science Associate, Merck Sharp and Dohme, P.O. Box 7702, Yaounde, Cameroon, (Represents MSD in Chad, Central Africa Republic, Gabon, Democratic Republic of Congo, Congo and Equatorial Guinea), Tel: (237) 753 00 85 - E-mail: tatangmoa@yahoo.fr Mission to Save the Helpless (MITOSATH) 82. Mrs Francisca OLAMIJU, Executive Director, 605 Hospital Place, Opposite Green Valley, Suites, GRA, Jos Plateau State, Nigeria Tel: (234) 073 464794 – Fax: (234) 464792 – E-mail: olamijufo@mitosath.org or mitosath@hotmail.com Organisation Ouest Africaine de la Santé/West African Health Organization 83. Dr Doulaye SACKO, Coordonnateur de Vision 2020, Organisation Ouest Africaine de la Santé, 01 B.P. 153, Bobo-Dioulasso, Burkina Faso Tel : (226) 20 97 57 79 – Fax : (226) 20 97 57 75 –E-mail : wahooasàwahooas.org, bayesack.2000@yahoo.fr Organisation pour la Prévention de la Cécité (OPC) 84. Dr Bernard PHILIPPON, Chargé de mission, Organisation pour la Prévention de la Cécité (OPC), 17 Villa d’Alésia, 75014 Paris, France Tel : (331) 40 44 94 04 - Fax : (331) 40 44 94 04 – E-mail :abphilippon@yahoo.fr Perspective 85. Mr Alexander TATAH ENYONG, Policy and Programme Advisor, Perspective, Yaounde, Cameroon Tel: (237) 993 94 59 – E-mail: a.tatah@yahoo.com Schistosomiasis Control Initiative – Partners for Parasite Control 86. Prof Alan FENWICK, Professor of Tropical Parasitology, Department of Infectious Diseases Epidemiology, Inperial College, St Mary’s, Paddigton Tel: 0207 594 3418 – Mobile: 07811 708313 – E-mail: a.fenwick@imperial.ac.uk - Website: www.schisto.org JAF12.10 Page 27 87. Mr Howard THOMPSON, Programme Manager, Schistosomiasis Control Initiative (SCI), Imperial College of Science and Medicine, Department of Infectious Disease Epidemiology, Faculty of Medicine, St Marys Campus, Norfolk Place, London W2 1 PG Tel: 020 7594 3404 – Fax: 020 7262 8140 – E-mail: howard.thompson@ic.ac.uk Sight Savers International (SSI) 88. Ms Catherine CROSS, Manager, International Programmes, Sight Savers International, Grosvenor Hall, Bolnore Road, Haywards Heath, RH16 4BX, United Kingdom Tel: +44 1444 446600 – Fax: +44 1444 446677 – E-mail: ccross@sightsavers.org 89. Mr Simon BUSH, Regional Director, West Africa, Sight Savers International, 58 Patrice Lumumba Road, P.O. Box KIA 18190, Airport, Accra, Ghana Tel: + 233 21 774210/784702 – Fax: +233 21 774209 –E-mail: sbush@sightsavers.org.gh OMS/SIEGE/GENEVE – WHO/HQ/GENEVA 90. Dr Dirk ENGELS, Coordinator, Preventive Chemotherapy and Transmission Control (CDS/NTD/PCT), World Health Orgranization (WHO), 20 Avenue Appia, CH-1211 Geneva 27, Switzerland Tel: + (41 22) 791-3824 – Mobile: (+41 79) 475-5514 – Fax: (+41 22) 791-4777 – E- mail : engelsd@who.int Bureau du Conseiller Juridique/Legal Counsel 91. M. Claude Henri VIGNES, Bureau du Conseiller Juridique, CH 1211 Genève 27, Suisse Tel: (4122) 791 2638 - Fax: + (4122) 791 WHO/TDR 92. Dr. Boakye BOATIN, Coordinator Lymphatic Filariasis Research, WHO/TDR, 20 Avenue Appia, 1211 Geneva 27, Switzerland Tel: (4122) 791 2426 – Fax: (4122) 791 4774 – E-mail: boatinb@who.int 93. Dr. Jan H.F. REMME, Coordinator, Science Strategy, WHO/TDR, 20 Avenue Appia, 1211 Geneva 27, Switzerland Tel: (4122) 791 3815 – Fax: (4122) 791 4854 – E-mail: remmej@who.int Prevention of Blindness and Deafness/Department of Chronic Diseases and Health Promotion 94. Dr Tony UKETY, NGDO Coordinator for Onchocerciasis Control, Chronic Diseases Prevention and Management (CPM), Department of Chronic Diseases and Health Promotion, (CHP), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland Tel: + (41-22) 791-1450 – Fax: + (41-22) 791-4772 - E-mail: uketyt@who.int OMS/AFRO -WHO/AFRO 95. Dr Paul Samson LUSAMBA-DIKASSA, Director of Programme Management, World Health Regional Office for Africa, P.O. Box 6, Brazzaville, Republic of Congo Tel: 47 241 39311 – Fax: 47 241 39509 – E-mail: lusambap@afro.who.int JAF12.10 Page 28 MULTI DISEASE SURVEILLANCE CENTER (MDSC) 96. Dr Laurent TOE, Chef d’Unité Laboratoire, Centre de Surveillance Pluripathologique (MDSC), 01 B.P. 549 Ouagadougou 01, Burkina Faso, Tel: (226) 50 34 38 18 – (226) 50 34 28 75 – E-mail: toel@oncho.oms.bf SECRETARIAT OMS/ WHO SECRETARIAT 97. Dr Uche AMAZIGO, Directrice du Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : dirapoc@oncho.oms.bf 98. Dr Laurent YAMEOGO, Manager du Programme, Coordonnateur du Bureau du Directeur, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : yameogol@oncho.oms.bf 99. Dr Mounkaïla NOMA, Manager du Programme, Coordonnateur du Bureau du Directeur, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : nomam@oncho.oms.bf 100. M. Koffi Benoît AGBLEWONU, Administrateur du Budget et Finances, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : agblewonuk@oncho.oms.bf 101. Mme Edith OUEDRAOGO, Assistante Administrative chargée des Réunions, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : kaboree@oncho.oms.bf 102. Mme Patricia B. Y. MENSAH, Assistante Administrative, Unité de Distribution Durable du Médicament, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : mensahp@oncho.oms.bf EQUIPE D’EVALUATION EXTERNE D’APOC ET SIZ/APOC AND SIZ EXTERNAL EVALUATION TEAM 103. Dr. (Mrs) Catherine HODGKIN, Royal Tropical Institute (KIT), P.O. Box 95001, 1090 HA Amsterdam, The Netherlands Tel: 31 20 568 8349, Fax: 31 20 568 8444, E-mail: c.hodgkin@kit.nl 104. Prof. Adenike ABIOSE, SIZ External Evaluation Team Leader, P.O. Box 29771, Secretariat Main Office, Ibadan, Oyo State, Nigeria Tel: (234) 80 37 86 570 2 – E-mail: adenikeabioseo@yahoo.com; abiose@skannet.com; abiose@infoweb.com.ng INTERPRETES/INTERPRETORS 105. M. Christian STENERSEN, Interprète, Les Rossanets, F-01170 Segny (France) Tel : (334) 5041 7880 – E-mail : CSternersen@wmo.int JAF12.10 Page 29 106. Mlle Geneviève CLEMENT, Interprète, 80, rue de Meyrin, F-01210 Ferney-Voltaire, France (région de Genève) Tel : (334) 50 40 76 50 – 107. M. Victor IMBOUA-NIAVA, 3, Maple Crescent, DTD, Silver Bells 2, East Airport, Accra, Ghana Tel: (233) 21 811 934/935 - Fax : (233) 21 814 469 - E-mail : vimbouaniava@yahoo.com 108. Mme Safiétou BARRY, Traductrice/Interprète de conference (français-anglais- français), 09 B.P. 526 Ouagadougou 09, Burkina Faso Tel : (226) 37 12 22, Portable (226) 70 21 41 14, E-mail : safibar@fasonet.bf 109. Monsieur Michel KABORE, Traducteur/Interprète, 01 B.P. 1444, Ouagadougou 01, Burkina Faso, Tel: 50 36 13 83:70 27 05 96 RAPPORTEURS 110. Ms. Karen GREPIN, 21 Central Street, Aubundale, MA 02466, USA Tel : +1 617 332 5126 – Fax : +1 617 986 2450 – E-mail : grepin@fas.harvard.edu 111. Ms. Elissa V. KLINGER, 83 Beacon Street # 2 Somerville, MA 02143, USA Fax : +1 617-495-5418 – E-mail : eklinger6@yahoo.com PROGRAMME DE LUTTE CONTRE L’ONCHOCERCOSE EN AFRIQUE/ONCHOCERCIASIS CONTROL PROGRAMME (OCP) Bénin 112. Dr Moussa YAROU, Directeur de Cabinet du Ministre, Ministère de la Santé publique, 01 B.P. 882 Cotonou, République Bénin Fax : (229) 21 33 87 17 113. Dr Franck SINTONDJI, Coordonnateur National, Programme National de lutte contre l’Onchocercose (PNLO), B.P. 882, Cotonou, Bénin Tel : (229) 21 33 87 17/(229) 90 93 53 05 - Fax : (229) 21 33 87 17 - E-mail :sedjors@hotmail.com ; pnlo@intnet.bf Burkina Faso 114. Son Excellence Monsieur Bédouma Alain YODA, Ministre de la Santé, Ministère de la Santé publique, B.P. 7009, Ouagadougou, Burkina Faso Fax : (226) (226) 50 22 52 44/50 31 70 24 115. Dr Souleymane SANOU, Directeur Général de la Santé, Ministère de la Santé, B.P. 7009, Ouagadougou, Burkina Faso Tél : (226) 70 26 97 64/(226) 50 33 49 38 - Fax: (226) 50 32 52 44 - E-mail : Côte d’Ivoire 116. Mr Gueu Paul MAHAN, Premier Conseiller à l’Ambassade de Côte d’Ivoire à Yaoundé, B.P. V 1715, BASTOS Tel : (237) 221 32 91/601 19 58 – E-mail : m.gpaul@yahoo.fr JAF12.10 Page 30 117. Dr Bernard GUESSAN BI GOUZAN, Directeur de l’Information, de la Planification et de l’Evaluation (DIPE), Ministère de la Santé et de l’Hygiène publique, BP V4, Abidjan, République de Côte d’Ivoire s/c Représentation de l’OMS/Tel : (225) 22 51 72 04 - Fax : (225) 22 51 72 32 118. Dr Pepe Paul Maurice DOGBO, Coordonnateur National, Programme National de lutte contre l’Onchocercose, B. P. 6394, Abidjan 06, République de Côte d’Ivoire Tel : (225) 22 52 38 36/22 52 38 39 - Fax : (225) 22 52 38 35 - E- mail :pauldogbo@yahoo.fr Ghana 119. Honourable Samuel OWUSU-AGYEI, Deputy Minister of Health, P.O. Box M44, Accra, Republic of Ghana Tel: (233) 21 660 001 – Fax: (233) 21 670 076 - E-mail: sowa@afrionline.com.gh 120. Dr Kwadwo BIRITWUM, National Coordinator, Oncho/LF Programme, Health Research Unit, Ghana Health Service, Oncho Control Programme, P.O. Box GP 184, Accra, Ghana Tel: (233) 21 68 11 09 – Fax: (233) 21 22 67 39 – E-mail: nana.Biritwum@hru-ghs.org 121. Mr Stephen QUANSAH, Administrator, Ministry of Health, P.O. Box M-44, Accra, Ghana Tel: (023) 68 42 00 - Fax: (023) 66 38 10 Guinee Bissau 122. Dr. Julio César Sa NOGUEIRA, Assistant Technique du Ministre par la Politique de la Santé publique, Ministère de la Santé publique, Avenue Unidade Africana, B.P. 50, Bissau, Guinée Tel : (245) 21 24 24 – Fax : (245) 20 11 88 – E-mail :jcsnogueira@yahoo.com.bs 123. Dr Ramalho Joao CORREIA, Coordonnateur du Programme Onchocercose, Ministère de la Santé, Gabu, Guinée-Bissau Tel : (245) 21 24 24 – Fax : (245) 20 11 88 Guinée Conakry 124. Dr. Pogba GBANACE, Chef de Cabinet, Ministère de la Santé publique, B.P. 585, Conakry, République de Guinée Tel : (224) 30 41 20 32 125. Dr Nouhou Konkouré DIALLO, Coordonnateur National du Programme National de lutte contre l’onchocercose et la Cécité (PNLO), Ministère de la Santé publique, Programme Onchocercose – Cécité, B.P. 585, Conakry, République de Guinée Tél : (224) 25 3371 - Fax : (224) 433707 - E-mail : dnouhoufr@yahoo.fr Mali 126. Dr Oumar Mamadou TRAORE, Coordonnateur National du Programme de lutte contre l’onchocercose, Direction nationale de la Santé, Bamako, Mali Tel : (223) 222 64 97 – Fax : (223) 223 36 74 - E-mail : traoremot@yahoo.fr ou motraore@dnsmali.org JAF12.10 Page 31 Niger 127. Dr. Salissou ADAMOU BATCHIRI, Entomologiste National, Coordonnateur National, Programme National de lutte contre l’Onchocercose (PNLO), Ministère de la Santé publique et de la Lutte contre les Endémies, B.P. 623, Niamey, République du Niger Tel : (227) 72 28 79 – Fax : (227) 75 35 28 – E-mail : sadamouba@yahoo.fr Sénégal 128. Dr Moussa MBAYE, Secrétaire Général, Ministère de la Santé publique, Avenue Roume, Dakar, République du Sénégal Tel : (221) 869 42 44 – Fax : (221) 869 42 49 - E-mail : mspmsg@sentoo.sn 129. Dr. Lamine DIAWARA, Coordonnateur National, Programme National de lutte contre l’Onchocercose (PNLO), BP 59, Tambacounda, République du Sénégal Tel : (221) 981 11 64 – Fax : (221) 981 10 77 – Cellulaire : (221) 683 03 18 – E-mail : elddiawara@yahoo.fr Sierra Leone 130. Honourable Mr. Ibrahim SESAY, Deputy Minister of Health and Sanitation, Ministry of Health and Sanitation, 4th Floor, Youyi Building Brookfields, Freetown, Sierra Leone Tel: (232) 22 241 786 – Fax: (232) 22 241 786 – E-mail: deputyminister46@yahoo.co.uk 131. Dr Joseph B. KOROMA, Oncho Control Programme Manager, NOCP, Public Health Specialist, 7th Edmon Street, Wellington, Ministry of Health and Sanitation c/o WHO Sierra Leone, P.O. Box 529, Freetown, Sierra Leone Tel: (232) 76 779 838 – E-mail: jsphkoroma@yahoo.co.uk Togo 132. Prof. Kondi Charles AGBA, Ministre de la Santé, Ministère de la Santé, B.P. 386, Lomé, République du Congo Tel : (228) 222 62 41- Fax : (228) 222 20 73 - E-mail : agba.charles@dafitogo.tg 133. Dr Potchoziou KARABOU, Directeur Régional de la Santé, Coordonnateur National, Programme National de lutte contre l’Onchocercose (PNLO), B.P. 487, Kara, République du Togo Tel : (228) 660 17 10/902 47 95 – Fax : (228) 660 04 14 - E-mail : karaboup@yahoo.fr PARTICIPANTS DE LA SOCIETE NATIONALE D’ELECTRICITE/RDC 134. Dr Lianza EA LIANZA, Directeur du Département des Ressources Humaines de la Société Nationale d'Electricité (SNEL), B.P. 500 Kinshasa I, République démocratique du Congo Tel : (243) 81 700 54 49 – E-mail : dr_lianza_ea_lianza@yahoo.fr